Wegovy ® is the first FDA-approved weight-management medicine that lowers the risk of major cardiovascular events in adults with obesity and known heart disease. Health plans can be …

Weight loss in pounds (lb) calculated as 5%, 10%, 15%, and 20% of mean baseline body weight of Wegovy ® and placebo patients.

Wegovy (semaglutide) injection 2.4 mg is indicated for chronic weight management for adults with obesity and to reduce the risk of major adverse cardiovascular events in adults with obesity or …

May 13, 2024 · In the new analysis, the researchers reported that after two years, about 68% of people taking Wegovy had lost at least 5% of their body weight, while 21% of people on a …

The FDA granted the approval to Novo Nordisk A/S. Wegovy is also approved to reduce excess weight and maintain weight reduction long term in certain adults with obesity or overweight...

Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest …

Jan 17, 2025 · In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at 72 weeks compared to placebo or semaglutide 2.4 …

Jun 4, 2021 · Across the trials in people without type 2 diabetes, an average weight loss of 17-18% 1 sustained over 68 weeks was reported for people with obesity treated with Wegovy™. …

May 23, 2023 · In the study, patients who received a 50 mg daily dose of the treatment lost an average of 15.1% of their weight over 68 weeks, compared with a 2.4% average weight loss …

May 14, 2024 · Novo Nordisk ’s blockbuster GLP-1 analog Wegovy (semaglutide) can maintain meaningful weight loss for up to four years and improve cardiovascular health regardless of …